Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money

Executive Summary

Data showing IL-17 blockers Cosentyx and brodalumab beat J&J’s IL-12/23 inhibitor Stelara in psoriasis make a strong impression at the American Academy of Dermatology meeting, but that doesn’t necessarily mean they’ll be preferred.

You may also be interested in...



Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market

The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.

Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting

Additional data for J&J's guselkumab, Regeneron/Sanofi's Dupixent, Lilly's Taltz and UCB/Dermira's Cimzia featured at the American Academy of Dermatology meeting in Orlando, Fla. March 3-7.

Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel